Sirtuin modulating compounds and applications thereof
US-2024228431-A1 · Jul 11, 2024 · US
US11358947B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11358947-B2 |
| Application number | US-201816606200-A |
| Country | US |
| Kind code | B2 |
| Filing date | Apr 17, 2018 |
| Priority date | Apr 17, 2017 |
| Publication date | Jun 14, 2022 |
| Grant date | Jun 14, 2022 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
Provided herein are inhibitors of transmembrane protein 16A (TMEM 16A), a Ca 2+ -activated CI″ channel expressed widely in mammalian epithelia, as well as in vascular smooth muscle and some tumors and electrically excitable cells. TMEM16A inhibitors have potential utility for treatment or management of disorders of epithelial fluid and mucus secretion, hypertension, some cancers, pain, and other diseases.
Opening claim text (preview).
The invention claimed is: 1. A compound having one of the following structures (I-5), (I-6) or (I′-6) or a pharmaceutically acceptable salt, isotopic form, stereoisomer or prodrug thereof, wherein: R 1 is optionally substituted C 1 -C 6 alkylene or optionally substituted heteroalkylene; each R 2 is the same or different and independently hydrogen, methyl, ethyl, C 1 -C 6 alkoxy, C 1 -C 6 haloalkyl, or C 1 -C 6 haloalkoxy; and R 3 is C 1 -C 6 haloalkyl having at least two different halogens. 2. The compound of claim 1 , having one of the following structures (I-7), (I-8) or (I′-8): wherein: each R 2 is independently H, methyl, ethyl, C 1 -C 6 alkoxy, C 1 -C 6 haloalkyl, or C 1 -C 6 haloalkoxy; and R 3 is C 1 -C 6 haloalkyl having at least two different halogens. 3. The compound of claim 1 being: 2-(2-chloro-2,2-difluoro-acetylamino)-5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophene-3-carboxylic acid o-tolylamide; 2-(2-bromo-2,2-difluoro-acetylamino)-5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophene-3-carboxylic acid o-tolylamide; 2-(2,2-Difluoro-2-iodo-acetylamino)-5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophene-3-carboxylic acid o-tolylamide; 2-(2-chloro-2,2-difluoro-acetylamino)-5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophene-3-carboxylic acid phenylamide; 2-(2-bromo-2,2-difluoro-acetylamino)-5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophene-3-carboxylic acid phenylamide; or 2-(2,2-difluoro-2-iodo-acetylamino)-5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophene-3-carboxylic acid phenylamide. 4. The compound of claim 1 wherein R 2 is H, methyl, ethyl, trifluoromethyl, or trifluoromethoxy. 5. The compound of claim 4 , wherein R 3 is perhaloalkyl. 6. The compound of claim 5 wherein R 3 is chlorodifluoromethyl, bromodifluoromethyl, or difluoroiodomethyl. 7. A pharmaceutical composition comprising a physiologically acceptable excipient and a compound of claim 1 . 8. The pharmaceutical composition of claim 7 wherein the compound of Formula (I) is: 2-(2-chloro-2,2-difluoro-acetylamino)-5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophene-3-carboxylic acid o-tolylamide; 2-(2-bromo-2,2-difluoro-acetylamino)-5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophene-3-carboxylic acid o-tolylamide; 2-(2,2-Difluoro-2-iodo-acetylamino)-5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophene-3-carboxylic acid o-tolylamide; 2-(2-chloro-2,2-difluoro-acetylamino)-5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophene-3-carboxylic acid phenylamide; 2-(2-bromo-2,2-difluoro-acetylamino)-5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophene-3-carboxylic acid phenylamide; or 2-(2,2-difluoro-2-iodo-acetylamino)-5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophene-3-carboxylic acid phenylamide. 9. A compound selected from the group consisting of: 2-(2-chloro-2,2-difluoro-acetylamino)-5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophene-3-carboxylic acid (4-fluoro-phenyl)-amide; 2-(2-bromo-2,2-difluoro-acetylamino)-5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophene-3-carboxylic acid (4-fluoro-phenyl)-amide; and 2-(2,2-difluoro-2-iodo-acetylamino)-5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophene-3-carboxylic acid (4-fluoro-phenyl)-amide.
Antineoplastic agents · CPC title
condensed with rings other than six-membered or with ring systems containing such rings · CPC title
Seven-membered rings · CPC title
Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen · CPC title
Ortho-condensed systems · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.